12:00 AM
 | 
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MK-8931: Phase Ib data

A double-blind, placebo-controlled Phase Ib trial in 32 patients with mild to moderate AD showed that reductions in CSF beta amyloid 40 concentrations from baseline to day 7 were 57% for once-daily 12 mg oral MK-8931, 79% for once-daily 40 mg MK-8931 and 84% for once-daily 60 mg MK-8931. Additionally, reductions in beta...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >